Your browser is no longer supported. Please, upgrade your browser.
XOMA XOMA Corporation weekly Stock Chart
XOMA Corporation
Index- P/E- EPS (ttm)-1.35 Insider Own0.40% Shs Outstand8.51M Perf Week-7.01%
Market Cap115.14M Forward P/E- EPS next Y-1.31 Insider Trans- Shs Float7.79M Perf Month0.00%
Income-11.20M PEG- EPS next Q-0.49 Inst Own49.10% Short Float14.72% Perf Quarter-16.48%
Sales9.00M P/S12.79 EPS this Y108.20% Inst Trans-0.31% Short Ratio11.69 Perf Half Y-36.54%
Book/sh0.14 P/B96.64 EPS next Y24.30% ROA-25.60% Target Price31.00 Perf Year-57.56%
Cash/sh3.34 P/C4.05 EPS next 5Y19.00% ROE-257.70% 52W Range11.88 - 37.25 Perf YTD-61.99%
Dividend- P/FCF- EPS past 5Y15.20% ROI72.20% 52W High-63.68% Beta2.61
Dividend %- Quick Ratio5.40 Sales past 5Y9.30% Gross Margin- 52W Low13.89% ATR1.03
Employees13 Current Ratio5.40 Sales Q/Q-97.50% Oper. Margin- RSI (14)40.25 Volatility6.04% 6.81%
OptionableNo Debt/Eq0.00 EPS Q/Q-127.50% Profit Margin- Rel Volume0.84 Prev Close13.53
ShortableYes LT Debt/Eq18.33 EarningsNov 05 Payout- Avg Volume97.98K Price13.53
Recom2.00 SMA20-9.02% SMA50-5.96% SMA200-31.16% Volume0 Change0.00%
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-22-15Downgrade Ladenburg Thalmann Buy → Neutral
Oct-10-14Resumed ROTH Capital Buy $9
Apr-29-14Upgrade MLV & Co Hold → Buy $7
Mar-11-14Downgrade MLV & Co Buy → Hold $8 → $7
Mar-05-14Reiterated Ladenburg Thalmann Buy $6.50 → $10
Oct-31-13Reiterated MLV & Co Buy $7.50 → $8
May-09-13Reiterated Ladenburg Thalmann Buy $5 → $6
May-14-12Initiated Cowen & Co Outperform
Mar-31-11Reiterated MLV Capital Buy $12 → $10
Mar-23-11Reiterated RBC Capital Mkts Outperform $8 → $6
Jan-06-11Reiterated Ladenburg Thalmann Buy $12 → $16
Jan-04-11Reiterated Wedbush Outperform $12 → $16
Dec-18-18 04:43PM  XOMA Announces Closing of Rights Offering GlobeNewswire
Nov-19-18 04:30PM  XOMA Announces Commencement of Rights Offering GlobeNewswire
Nov-07-18 11:55AM  Xoma (XOMA) Reports Q3 Loss, Tops Revenue Estimates Zacks +8.35%
10:52AM  Xoma: 3Q Earnings Snapshot Associated Press
07:05AM  XOMA Announces Proposed Rights Offering GlobeNewswire
07:00AM  XOMA Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-30-18 08:05AM  Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors GlobeNewswire
Oct-29-18 10:31AM  Xoma (XOMA) Q3 Earnings Preview: What's Shaping Up? Zacks
Oct-25-18 08:15AM  Analysis: Positioning to Benefit within Middlesex Water, On Deck Capital, New Relic, Toro, XOMA, and ESCO Technologies Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -7.49%
Sep-27-18 04:30PM  XOMA to Present at the Cantor Fitzgerald Healthcare Conference 2018 and the 2018 BIO Investor Forum GlobeNewswire -6.07%
Sep-24-18 12:15PM  The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Could Be Important Simply Wall St. +5.68%
Sep-21-18 07:00AM  XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte GlobeNewswire
Aug-28-18 07:00AM  XOMA to Present at the H. C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-09-18 07:00AM  XOMA to Present at the 2018 Wedbush PacGrow Healthcare Conference and the 2018 Southern California Investor Conference GlobeNewswire
Aug-07-18 06:15PM  Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates Zacks
05:08PM  Xoma: 2Q Earnings Snapshot Associated Press
04:35PM  XOMA Reports Second Quarter 2018 Financial Results GlobeNewswire
07:40AM  Detailed Research: Economic Perspectives on Alleghany, Enable Midstream Partners, LP, XOMA, MCBC, Unifi, and Tyler Technologies What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-26-18 07:00AM  XOMA Added to the Russell 2000® and Russell 3000® Indexes GlobeNewswire
May-15-18 07:00AM  XOMA to Present at the UBS Global Healthcare Conference GlobeNewswire
May-09-18 06:11PM  Xoma: 1Q Earnings Snapshot Associated Press
04:05PM  XOMA Reports First Quarter 2018 Financial Results GlobeNewswire
May-08-18 07:00AM  XOMA Announces $20 Million Credit Facility with Silicon Valley Bank to Advance Royalty-Aggregator Business Model GlobeNewswire
May-02-18 07:30AM  New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares, and Alleghany Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Apr-03-18 07:00AM  XOMA to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire +5.89%
Mar-20-18 07:35AM  Investor Expectations to Drive Momentum within Key Energy Services, XOMA, Goldman Sachs BDC, Echo Global Logistics, Ellington Residential Mortgage REIT, and Phibro Animal Health Discovering Underlying Factors of Influence GlobeNewswire
Mar-07-18 05:46PM  Xoma reports 4Q loss Associated Press +7.78%
04:05PM  XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update GlobeNewswire
Mar-05-18 07:00AM  XOMA to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-19-18 10:04AM  AbbVie Presents New Data on Upadacitinib for Crohn's Disease Zacks
Feb-16-18 09:56AM  FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review Zacks
Feb-14-18 05:48PM  AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda Zacks
Feb-08-18 11:26AM  Theravance, J&J Ink Deal for Inflammatory Intestinal Drug Zacks
09:49AM  Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down Zacks
Feb-06-18 10:00AM  Pfizer Files for Xtandi in Early Stage Prostate Cancer Zacks
Feb-02-18 10:00AM  Puma, CANbridge Team Up to Commercialize Nerlynx in China Zacks
09:30AM  Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review Zacks
Jan-31-18 09:17AM  Puma & Medison Team Up to Commercialize Nerlynx in Israel Zacks
Jan-30-18 11:14AM  Theravance's NDA for COPD Candidate Gets FDA Acceptance Zacks
Jan-29-18 10:22AM  Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion Zacks
Jan-26-18 03:54PM  East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs American City Business Journals
Jan-25-18 10:30AM  Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y Zacks
10:29AM  Shire Gets FDA Nod for Cinryze Tech Transfer to New Site Zacks
Jan-24-18 03:22PM  EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down Zacks
Jan-23-18 11:30AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 InvestorPlace
10:45AM  Anthera's Sollpura Strong on Positive Futility in Phase III Zacks
09:42AM  Regeneron's Dupixent Receives MHLW Nod for Label Expansion Zacks
Jan-22-18 10:22AM  Bristol-Myers (BMY) Reports Data from CheckMate-142 Study Zacks
08:43AM  Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8% Zacks
Jan-17-18 09:36AM  Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It? Zacks
07:35AM  Recent Analysis Shows XOMA, Washington Real Estate Investment Trust, TransMontaigne Partners, Triumph, Hemispherx BioPharma, and Virtus Investment Partners Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jan-15-18 08:15AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 Zacks
Jan-12-18 12:46PM  Aradigm's Bronchiectasis Candidate Has Negative FDA Vote Zacks
10:05AM  Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock? Zacks
Jan-11-18 09:46AM  Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU Zacks
08:01AM  Why is Novo Nordisk Stock Up More Than 50% in Past Year? Zacks
Jan-10-18 09:00AM  Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up Zacks
Jan-09-18 04:35PM  Acorda's Shares Down on Disappointing Ampyra View for 2018 Zacks
09:58AM  Novo Nordisk Confirms Bid for Ablynx But Faces Rejection Zacks
Jan-08-18 03:00PM  It was a banner year for stocks, but not everyone shared in the wealth. American City Business Journals
08:49AM  The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines Zacks
07:00AM  XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel GlobeNewswire
Jan-05-18 04:25PM  4 Biotech Stocks to Watch in the New Year Zacks
09:47AM  Emergent Starts Phase II Study on Anti-influenza Candidate Zacks
Jan-04-18 09:58AM  United Therapeutics (UTHR) Collaborates With Corsair Pharma Zacks -5.63%
09:53AM  Pfizer (PFE) Collaborates With Sangamo for Gene Therapy Zacks
Jan-03-18 01:40PM  Thermo Fisher Buys Phenom-World, Aids Analytical Instruments Zacks
09:41AM  Inovio Amends Chinese Deal for Immunotherapy, Shares Up Zacks
06:34AM  3 Best Healthcare Stocks of 2017 Motley Fool
03:04AM  Anika Therapeutics Receives FDA Nod for Bone Repair Therapy Zacks
Jan-02-18 09:09AM  PetMed Rides on Solid Reorders & New Orders Amid Competition Zacks
Dec-28-17 08:07AM  5 of the Best-Performing Biotech Stocks of 2017 Zacks
Dec-27-17 12:05PM  ETFs with exposure to XOMA Corp. : December 27, 2017 Capital Cube
Dec-20-17 03:44PM  3 Buy-Ranked Biotech Stocks That Soared in 2017 Zacks
02:21PM  Pfizer's Leukemia Drug Gets FDA Nod in First-Line Setting Zacks
07:43AM  Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies Zacks
Dec-19-17 10:30AM  Pfizer Hikes Dividend, Announces $10B Share Buyback Plan Zacks
07:30AM  Free Post Earnings Research Report: XOMAs Revenue Grew 5597.6% ACCESSWIRE
Dec-18-17 08:23AM  Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran Zacks
Dec-17-17 09:09AM  The 3 Best Biotech Stocks of 2017 Motley Fool
Dec-11-17 02:17PM  ETFs with exposure to XOMA Corp. : December 11, 2017 Capital Cube
07:01AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-08-17 08:10AM  Todays Research Reports on Stocks to Watch: Halozyme Therapeutics and Xoma Corporation ACCESSWIRE
Dec-07-17 08:35AM  XOMA Announces Exclusive License Agreement for XOMA 358 with Rezolute, Inc. GlobeNewswire +13.39%
08:30AM  AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc. GlobeNewswire
Dec-01-17 05:28PM  4 Biotech Stocks to Better Your Financial Health This Winter Zacks
Nov-30-17 02:40PM  ETFs with exposure to XOMA Corp. : November 30, 2017 Capital Cube +10.70%
Nov-29-17 08:43AM  XOMA Corp. :XOMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube -6.58%
Nov-10-17 05:14PM  Xoma: A Lower Risk Way Of Investing In Biotech Forbes +6.36%
Nov-06-17 05:28PM  Xoma beats 3Q profit forecasts Associated Press
04:05PM  XOMA Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-29-17 11:41AM  3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year Motley Fool
Oct-04-17 09:15AM  XOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries GlobeNewswire
Sep-19-17 07:00AM  XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-11-17 07:00AM  XOMA Earns $3 Million Milestone Payment from its License Agreement with Nanotherapeutics GlobeNewswire
Sep-07-17 02:17PM  ETFs with exposure to XOMA Corp. : September 7, 2017 Capital Cube +12.60%
Sep-06-17 08:10AM  Today's Research Reports on Stocks to Watch: Insmed Inc. and XOMA Corporation ACCESSWIRE
07:20AM  [$$] Novartis Deal Could Send Xoma Stock to $19
07:00AM  XOMA to Present at the Rodman and Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-28-17 08:20AM  Today's Research Reports on Stocks to Watch: Adamas Pharmaceuticals and XOMA Corporation ACCESSWIRE
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/IL10% OwnerDec 13Buy14.4124,253349,525693,541Dec 13 06:54 PM
BVF PARTNERS L P/IL10% OwnerDec 12Buy14.752,81041,448669,288Dec 13 06:54 PM
BVF PARTNERS L P/IL10% OwnerDec 11Buy14.509,400136,270666,478Dec 13 06:54 PM
BVF PARTNERS L P/IL10% OwnerDec 10Buy14.5418,081262,972657,078Dec 10 07:03 PM
BVF PARTNERS L P/IL10% OwnerDec 07Buy14.7732,015472,778638,997Dec 10 07:03 PM
BVF PARTNERS L P/IL10% OwnerDec 06Buy14.8010,927161,698606,982Dec 10 07:03 PM
BVF PARTNERS L P/IL10% OwnerDec 04Buy14.994,17162,515596,055Dec 04 07:01 PM
BVF PARTNERS L P/IL10% OwnerDec 03Buy14.9080612,009591,884Dec 04 07:01 PM
BVF PARTNERS L P/IL10% OwnerNov 30Buy14.854,82371,615591,078Dec 04 07:01 PM
BVF PARTNERS L P/IL10% OwnerNov 29Buy14.9310,016149,543586,255Nov 29 05:55 PM
BVF PARTNERS L P/IL10% OwnerNov 28Buy15.118,288125,262576,239Nov 29 05:55 PM
BVF PARTNERS L P/IL10% OwnerNov 27Buy15.2411,396173,680567,951Nov 29 05:55 PM
BVF PARTNERS L P/IL10% OwnerNov 21Buy15.0025,000374,893556,555Nov 21 05:42 PM
BVF PARTNERS L P/IL10% OwnerNov 20Buy13.6837,482512,701531,555Nov 21 05:42 PM
BVF PARTNERS L P/IL10% OwnerNov 19Buy13.939,771136,064494,073Nov 21 05:42 PM
BVF PARTNERS L P/IL10% OwnerNov 16Buy13.8210,849149,986484,302Nov 19 10:21 AM
VAN NESS W DENMANDirectorNov 15Option Exercise6.857,69352,69914,672Nov 16 04:31 PM
BVF PARTNERS L P/IL10% OwnerNov 15Buy13.3121,141281,361473,453Nov 19 10:21 AM
VAN NESS W DENMANDirectorNov 15Sale12.675,52870,0409,144Nov 16 04:31 PM
Neal James RCEONov 13Buy13.264,00053,05620,333Nov 15 04:09 PM
BURNS THOMAS M.SVP, Finance & CFOApr 27Option Exercise5.502,65514,6039,210Apr 27 05:44 PM
Neal James RCEOApr 27Option Exercise5.5015,65586,10331,988Apr 27 05:44 PM
Neal James RCEOApr 27Sale24.4215,655382,23616,333Apr 27 05:44 PM
BURNS THOMAS M.SVP, Finance & CFOApr 27Sale24.772,65565,7576,555Apr 27 05:44 PM
BURNS THOMAS M.SVP, Finance & CFOApr 26Option Exercise5.508,34545,89814,900Apr 27 05:44 PM
Neal James RCEOApr 26Option Exercise5.508,34545,89824,678Apr 27 05:44 PM
Neal James RCEOApr 26Sale24.698,345206,05016,333Apr 27 05:44 PM
BURNS THOMAS M.SVP, Finance & CFOApr 26Sale24.698,345206,0506,555Apr 27 05:44 PM